Home
About
Overview
Sharing Data
ORCID
Help
History (76)
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
Will a 5-ASA a day keep the cancer (and dysplasia) away?
KB Cells
Pediatric epilepsy syndromes with associated developmental impairment.
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
See All 76 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
View in:
PubMed
subject areas
Adult
Antibodies, Monoclonal, Humanized
Crohn Disease
Discriminant Analysis
Drug Administration Schedule
Female
Humans
Immunosuppressive Agents
Infusions, Intravenous
Kaplan-Meier Estimate
Male
Middle Aged
Natalizumab
Retrospective Studies
Tertiary Care Centers
Treatment Outcome
United States
authors with profiles
Stephen B. Hanauer
Russell Cohen
David Rubin